47results about How to "Strong binding specificity" patented technology

A compound, which is used for the diagnosis and the prophylaxis/treatment of diseases in which prion protein is accumulated, or specific staining of abnormal prion protein in samples, represented by the formula (I) or (II):

or a salt or solvate thereof.

The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10⁻¹⁰ M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.

The invention provides a method for detecting miRNA based on polymerase chain reaction comprising EvaGreen dye, and the use of EvaGreen dye in elevating the binding specificity of primers to templates in PCR.

Specific detection of proteolytic enzymes is achieved by extinguishing dye fluorescence by the amino acid tryptophan. Ttyptophan is disposed on one side of the cutting site of a proteolytic enzyme while an amino acid marked with a dye is arranged on the other side. Extinction of fluorescence occurs prior to enzyme cutting. Spatial separation of the tryptophan and the dye takes place after cutting, whereby fluorescence extinction does not occur. The dye can then fluoresce and a signal increase occurs thereby indicating that cutting has been carried out and the presence of the enzyme.

The present invention relates to dimeric pentadentate chelators with exceptionally strong binding of metal ions, for detection, immobilization and purification of biomolecules. Dimeric chelators offer a cooperativity of binding of two adjacent immobilized metal ions simultaneously to a histidine-tagged biomolecule, which gives advantageous properties regarding strength of binding compared to a corresponding monomer chelator. In addition, a dimer increases the selectivity (ease of separation) against non-tagged biomolecules with low metal-ion affinity.

The dimeric pentadentate chelator according to the invention has the following general formula:

wherein

Sc is a scaffold or a connecting structure that contains at least two functional groups enabling coupling of two pentadentate chelators (PD), and

PD is a pentadentate chelator having the formula:

Disclosed is a preparation method of the poly pyrrole-polycarbonate composite membrane of the supported Cibacron Blue, which relates to the preparation technique of the affinity membrane used for the separation and purification of the protein, the invention provides the preparation method of the poly pyrrole-polycarbonate composite membrane of the supported Cibacron Blue having good hydrophilic property and excellent biocompatibility. The invention takes the polycarbonate membrane as the basement membrane, the basement membrane is fixed in the middle of the diffusion pool containing double pools after the pretreatment in the Cibacron Blue solution; the oxidant and pyrrole monomer solution are respectively added into each pool of the diffusion pool that contains two pools; the active ligand Cibacron Blue is added into any pool of the diffusion pool with the reaction temperature being controlled between 0-40 DEG C and the reaction time is 0.5-8h; finally the poly pyrrole-polycarbonate composite membrane of the supported active ligand Cibacron Blue can be obtained after the cleaning treatment of the basement membrane when the reaction finishes. The prepared affinity membrane has great chemical durability, hydrophilic property and excellent biocompatibility. The composite membrane can be used for separation and purification of protein.

The invention relates to the technical field of engineered antibody and provides a monoclonal antibody. The variable region of heavy chain of the monoclonal antibody contains the amino acid sequences shown in SEQ ID NO.1, SEQ ID NO.2 and SEO ID NO.3; the variable region of light chain of the monoclonal antibody contains the amino acid sequences shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The invention also specifically provides a humanization single-chain antibody generated by the recombinant strain of enterotoxigenic Escherichia coli with the accession number CGMCC No.2820 and the amino acid sequence of the humanization single-chain antibody is shown in SEQ ID NO.7. The antibody of the invention can be specifically bound with A-beta oligomer, effectively inhibit the fibrosis aggregation of A-beta and obviously alleviate the toxic effect of the A-beta on cells. The invention also relates to a pharmaceutical composite containing the antibody. The antibody of the invention has strong activity, good specificity, easy preparation and wide prospect of experiment application and clinical application.

A fully humanised antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling.

The invention relates to an aromatic hydrocarbon receptor (AhR) and an immune detection method of an antibody mediated therewith. The method includes the steps of: 1) separating and purifying the AhR from livers of carps, and combining the AhR with PAHs to prepare a coated antigen and adsorbing the coated antigen on a solid phase carrier; 2) adding a to-be-tested PAHs sample, the AhR and a corresponding antibody, so that the PAHs-AhR on the solid phase and the to-be-tested PAHs-AhR are subjected to a competitive reaction with the antibody; 3) after the reaction, adding enzyme-labeled secondary antibody, and finally performing detection in a substrate color developing manner; 4) according to standard series of known PAHs and OD value of the to-be-tested sample, calculating inhibition rate, and according to the logarithmic relationship between the inhibition rate and concentration of the PAHs, drawing a graph to obtain a standard curve, and calculating the concentration of the to-be-tested PAHs. The method is used for performing trace-amount PAHs in water body by means of the AhR antibody, is high in detection specificity and simple in operations, is high in sensitivity, is less in usage amount of sample, and can be used for in-situ detection.

The present invention relates to a cancer kit containing a monoclonal antibody of specific binding ROS1. The monoclonal antibody is obtained by taking an ROS1 kinase domain obtained by screening as anantigen and immunizing a mouse. The antibody has the relatively good binding specificity, and it is verified that the antibody has the function of inhibiting the growth of tumor cells, so that the kit has the relatively good application prospect.

The invention discloses a fluorescent tracing system and method suitable for researching in-vitro and in-vivo distribution of lipidosome, and the method is based on a biological orthogonal reaction principle and is combined with fluorescent tracing technology. The system mainly comprises a trans-cyclooctene liposome and a tetrazine fluorescent probe. By adopting the method, the in-vitro and in-vivo distribution of the drug-loaded liposome can be researched, and a convenient and feasible method is provided for researching the in-vivo distribution of the liposome.

The invention discloses an anti-interferon alpha-2b nanobody and application thereof. The anti-interferon alpha-2b nanobody comprises one or two VHH chains, wherein the VHH chain consists of frameworkregions and complementary determining regions, wherein the complementary determining regions consist of CDR1 as shown in SEQ ID NO:1, CDR2 as shown in SEQ ID NO:2 and CDR3 as shown in SEQ ID NO:3; and the framework regions consist of FR1 as shown in SEQ ID NO:4, FR2 as shown in SEQ ID NO:5, FR3 as shown in SEQ ID NO:6 and FR4 as shown in SEQ ID NO:7. The invention also comprises application of the anti-interferon alpha-2b nanobody. According to the anti-interferon alpha-2b nanobody and the application thereof, the anti-interferon alpha-2b nanobody has the advantages of high stability, high specificity, small molecular weight, and being suitable for large-scale production; and can be made into a purification column for the purification of the interferon alpha-2b, and can also be made intoa secondary antibody reagent for the detection of the interferon alpha-2b, so that the anti-interferon alpha-2b nanobody has a broad application prospect.

The invention relates to the field of manufacturing of a sensor, particularly relates to a quality sensor for gene detection, and provides a quality sensor for gene detection. The quality sensor comprises a quality sensor body. The quality sensor is characterized in that a polyethylene glycol monolayer is arranged on the surface of a non-detected sensitive position of the quality sensor; a thiol biotin monolayer is arranged on the surface of the detected sensitive position of the quality sensor; a streptavidin layer is grafted on the thiol biotin monolayer. The quality sensor provided by the invention has the main advantages of real-time online detection, accurate result, fast detection speed, economic cost and good expansibility.